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Thioredoxina b s t r a c t
Acrolein, a reactive aldehyde found in cigarette smoke, is thought to induce its biological effects
primarily by irreversible adduction to cellular nucleophiles such as cysteine thiols. Here, we demon-
strate that acrolein rapidly inactivates the seleno-enzyme thioredoxin reductase (TrxR) in human
bronchiolar epithelial HBE1 cells, which recovered over 4–8 h by a mechanism depending on the
presence of cellular GSH and thioredoxin 1 (Trx1), and corresponding with reversal of protein–acro-
lein adduction. Our ﬁndings indicate that acrolein-induced protein alkylation is not necessarily a
feature of irreversible protein damage, but may reﬂect a reversible signaling mechanism that is reg-
ulated by GSH and Trx1.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cross-linking, or aggregation [10]. Among the spectrum of biologi-Acrolein (2-propenal) is a reactive a,b-unsaturated aldehyde
and a common environmental pollutant originating from organic
combustion, and is also generated as a endogenous metabolite in
biological systems resulting from various oxidative processes
[1,2]. The biological actions or toxicity of acrolein are related to
its electrophilic character, promoting covalent reactions with
cellular nucleophiles such as GSH, protein cysteine, histidine, and
lysine residues, and nucleophilic DNA bases. Because acrolein is a
major component of tobacco smoke, it is believed to contribute
the development of smoking-related diseases such as COPD,
asthma, or lung cancer [3,4]. However, acrolein also shares its
electrophilic character with many biological electrophiles with
presumed functional properties mediated by electrophile signaling
[5,6].
The toxicity of acrolein is generally thought to be mediated by
depletion of cellular GSH or disruption of cellular redox systems,
but may also be related to covalent protein modiﬁcations leading
to loss of protein function [7] or protein miss-folding [8,9],cally relevant electrophiles, there is a degree of selectivity with re-
spect to their reactivity with nucleophiles, based on the ‘‘hard/soft’’
acid–base principle [11]. Acrolein, as well as other a,b-unsaturated
aldehydes or ketones (which include lipid-derived oxidation prod-
ucts such as 4-hydroxy-2-nonenal or cyclopentenone prostaglan-
dins) are known as ‘‘soft’’ electrophiles, and therefore
preferentially target ‘‘soft’’ nucleophiles, primarily (protein) cys-
teine residues. Indeed, kinetic and proteomic data indicate that
acrolein preferentially reacts with cysteine residues compared to
histidine or lysine residues, which are ‘‘harder’’ nucleophiles
[7,12,13]. It has been suggested that toxicity associated with acro-
lein and other a,b-unsaturated aldehydes originates largely from
disruption of reversible redox signaling mechanisms, due to more
irreversible alkylation of selected sensitive cysteine residues that
are also subject to oxidative or nitrosative signaling [14]. Alterna-
tively, the toxic effects of a,b-unsaturated aldehydes such as acro-
lein, compared to e.g. endogenously generated cyclopentenone
prostaglandins, are thought to be related to the fact that the former
are slightly ‘‘harder’’ electrophiles and are more reactive to ‘‘hard-
er’’ nucleophiles such as lysine of amino groups in DNA bases in
addition to cysteine, especially at higher concentrations [15].
In spite of available evidence for preferred reactivity of acrolein
with cysteine thiols or thiolates, which is several orders of magni-
tude greater compared to reactions with other nucleophiles such
as lysine residues [14], the main existing evidence for formation
of acrolein-protein adducts in vivo is based on immunological
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myl-3,4-dehydropiperidino)lysine (FDP-lysine) or Ne-(3-methylpy-
ridinium)lysine (MP-lysine). In contrast, relatively little direct
evidence exists to date for generation of acrolein-cysteine adducts,
and no reports exist of speciﬁc acrolein-cysteine adducts in vivo,
which is attributed to the relatively limited stability of such
adducts even in in vitro systems and secondary reactions of pro-
tein–acrolein adducts by Schiff base formation [12].
Several detoxiﬁcation systems have been shown to metabolize
either the unsaturated double bond or the carbonyl moiety of acro-
lein and other a,b-unsaturated aldehydes, including GSH and glu-
tathione S-transferase (GST) [16], aldehyde dehydrogenase [17],
alkenal/one oxidoreductase [18], and aldo/keto reductase [19],
and thereby control their biological actions. In contrast, much less
is known about the fate of initially formed protein Michael adducts
by these electrophiles. Covalent protein adducts of a,b-unsaturated
aldehydes may be removed by lysosomal degradation and autoph-
agy [20]. Alternatively, it is feasible that Michael adducts, espe-
cially with cysteine, are reversed by cellular reducing systems,
which would help explain the relative paucity of demonstrated
protein-cysteine adducts in vivo. The reversible nature of
acrolein-cysteine adducts is supported by several in vitro studies
of Michael addition of electrophiles with GSH, which indicated
GST-catalyzed retro-Michael cleavage of GSH conjugates [21–23].
Moreover, such reversibility of cysteine adduction by biologically
relevant electrophiles would also support their proposed roles in
biological signaling pathways. The objective of the present study
was to evaluate the reversible nature of acrolein-dependent inacti-
vation of the seleno-enzyme thioredoxin reductase (TrxR), an
important susceptible target for acrolein and other electrophiles
[24–26]. Our ﬁndings demonstrate that recovery of TrxR activity
after its inactivation by acrolein relies importantly on the presence
of cellular GSH and thioredoxin-1 (Trx1), and indicate the involve-
ment of these redox systems in reversing acrolein adducts with
TrxR and other target proteins.2. Methods
2.1. Cell culture and treatments
Human bronchial epithelial (HBE1) cells (generously provided
by Dr. Reen Wu at the University of California, Davis [27]) were
cultured at 37 C in 95% humidiﬁed air containing 5% CO2 using
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM/F-12) supplemented
with 50 U/ml penicillin, 50 lg/ml streptomycin, 10 ng/ml cholera-
toxin (List Biological Laboratories, Inc.), 10 ng/ml epidermal
growth factor (Calbiochem), 15 lg/ml bovine pituitary extract,
0.5 mg/ml bovine serum albumin (Invitrogen), 5 lg/ml insulin,
5 lg/ml transferrin, and 0.1 lM dexamethasone (Sigma). For
experimentation, cells were plated in 12-well plates and cultured
to conﬂuence and placed in 2 ml Hank’s Balanced Salt Solution
(HBSS) for treatments with acrolein (to avoid unwanted reactions
of acrolein with other constituents present in the culture media),
and collected after 30 min for various biochemical analyses, or
placed in full culture media for continued incubation. At indicated
time points, cells were collected in appropriate lysis buffer for the
various analyses described below. Effects on cell viability were as-
sessed by analysis of LDH release (Pierce).
Where indicated, cells were pretreated with 10 lM MG132
(Calbiochem), to inhibit proteasomal degradation, by pretreatment
for 30 min prior and during acrolein treatment, and MG132 was
again added to the culture media during subsequent incubation.
Similarly, cells pretreated for 30 min with 10 lg/ml cycloheximide
(CHX; Sigma), to inhibit protein synthesis, which was continued
after acrolein treatment for the duration of the experiment.2.2. Analysis and alteration of cellular GSH levels
GSH was analyzed in cell lysates by derivatization with 2 mM
monobromobimane (mBrB), and analyzed by HPLC with ﬂuores-
cence detection, as previously published [28]. Where indicated,
GSH synthesis was inhibited by addition of 100 lM buthionine sul-
foximine (BSO; Sigma) after acrolein treatment.
2.3. SiRNA silencing of Trx1
To suppress endogenous Trx1 levels, cells were seeded at 70%
conﬂuence in 24-well plates and transfected with 50 nM TXN1
Smartpool siRNA (Dharmacon) or Non-Targeting siRNA using
DharmaFECT transfection reagent according to the manufacturer’s
instructions. Media was replaced after 24 h and cells were used for
experimentation 60 h after transfection.
2.4. Measurement of TrxR activity using insulin assay
Cells were lysed in 50 mM Tris/Cl (pH 7.4) containing 1 mM
EDTA, and the reductase activity of TrxR was measured using a pre-
viously described end-point insulin assay [29,30]. Protein lysates
(20 lg) were incubated with 2 mM NADPH, 20 lM E. coli thiore-
doxin (Trx), and 1.5 mg/ml insulin for 60 min at 37 C after which
the reaction was stopped with 8 M guanidine.HCl containing 1 mM
5,50-dithiobis(2-nitrobenzoic) acid (DTNB). Formation of 2-nitro-5-
thiobenzoic acid (TNB) was measured at 412 nm using a BioMate 5
spectrophotometer (Thermo Spectronic), and Trx-dependent
reductase activity was determined by calculating the difference
in activity with and without Trx.
2.5. Western blotting
Cell lysates were prepared by collecting cells in lysis buffer,
containing 1% Triton X-100, 250 mM NaCl, 50 mM HEPES, 10%
glycerol, 1.5 mM MgCl2, 1 mM polymethylsulfonyl chloride
(PMSF), 1 mM EGTA, 2 mM sodium orthovanadate (Na3VO4),
10 lg/ml aprotinin, and 10 lg/ml leupeptin for 15 min on ice, after
which cell suspensions were sonicated for 20 pulses on ice using a
sonic dismembrator (Fisher Scientiﬁc), and centrifuged
(14000 rpm, 4 C) for 5 min to remove cell debris. Protein was
quantiﬁed via the bicinchoninic acid assay (BCA protein assay
kit; Pierce). Aliquots containing 15 lg protein were mixed with
2 reducing sample buffer (containing 4% SDS, 20% glycerol, and
10% b-mercaptoethanol), and separated by SDS–PAGE, transferred
to nitrocellulose membranes, and blotted for speciﬁc proteins with
the following primary antibodies: TrxR1: (1:1000, Abcam), Trx1
(1:2000, Cell Signaling), HO-1 (1:250, Biovision), Cell Signaling),
JNK1/2 (1:1000, Cell Signaling), b-actin (1:5000, Sigma). Primary
antibodies were detected using HRP-conjugated anti-rabbit or
anti-mouse IgG and visualized by SuperSignal West chemilumines-
cent substrate (Pierce).
2.6. Detection of protein–acrolein adducts using biotin hydrazide
labeling
Protein lysates (P300 lg) were mixed with 5 mM biotin hydra-
zide (Thermo Scientiﬁc) solubilized in DMSO at room temperature
for 2 h with constant rotation, followed by addition of 15 mM NaC-
NBH4 and incubation on ice for 60 min. Biotin-labeled proteins
were puriﬁed by avidin chromatography as described previously
[31]. Brieﬂy, derivatized lysates were washed 3 times with 300 ll
of 20 mM Tris/Cl pH 7.4 using centrifugal ﬁlter devices (3000
MWCO; Millipore) at 10000 rpm for 10 min, to remove excess
biotin hydrazide and NaCNBH4. Labeled proteins were then
isolated by afﬁnity chromatography by the addition of 50 ll of a
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Scientiﬁc). Beads were washed 6 times with 0.2 M glycine pH 2.8,
centrifuged between each wash at 62500 rpm, then washed once
with 20 mM Tris/Cl pH 7.4. Proteins were eluted in 100 ll 2
reducing sample buffer and boiled at 95–100 C for 5 min, for anal-
ysis by SDS–PAGE and detection of biotin-labeled proteins by blot-
ting with streptavidin-HRP (1:20000) or Western blotting for
proteins of interest, as described above.
2.7. Statistical analyses
Data for each group were statistically analyzed via t-test or
analysis of variance (ANOVA) depending on the amount of
groups/experiment and signiﬁcance was assigned at a maximum
cut off of P < 0.05.
3. Results
3.1. Acrolein induces reversible depletion of GSH and reversible
inactivation of TrxR
In agreement with earlier ﬁndings [32,33], exposure of HBE1
cells to non-toxic doses of acrolein (30 lM) rapidly and transiently
depleted cellular GSH, which was regenerated to initial levels with-
in 2–4 h and to levels exceeding initial levels at later time points
(8–24 h), due to induction of GSH synthesis (Fig. 1A). Similarly,
acrolein exposure also rapidly inhibited TrxR activity, consistent
with earlier ﬁndings [34]. Contrary to a recent report [35], but in
accordance with earlier ﬁndings [30,34], TrxR activity was also re-
versed after acrolein treatment, to near control levels over 4–24 h
(Fig. 1A). Previous studies suggested that such TrxR recovery is due
to induction of TrxR1 mRNA expression [33], however, we did notFig. 1. Reversible GSH depletion and inactivation of TrxR after acute acrolein
exposure. HBE1 cells were exposed to 30 lM acrolein for 30 min, and subsequently
incubated for up to 24 h. (A) Cellular GSH levels (closed symbols) and TrxR activity
(open symbols) were analyzed at indicated times after acrolein treatment, using
HPLC and insulin assay, respectively. Data points represent mean ± S.E.M. (n = 4).
⁄⁄P < 0.01, #P < 0.001. Signiﬁcance was designated after analysis by one-way
ANOVA. (B) Western blot analysis of TrxR1 protein and b-actin at various time
points after acrolein treatment (30 lM). A representative blot of 3 separate
experiments is shown.observe signiﬁcant increases in TrxR1 protein levels over the same
time period (Fig. 1B).
To more directly evaluate the importance of de novo TrxR pro-
tein synthesis in recovery of TrxR activity after acrolein exposure,
HBE1 cells were pretreated with protein synthesis inhibitor CHX
prior to acrolein treatment. As shown in Fig. 2A, recovery of TrxR
activity after 8 h post-incubation following acrolein exposure was
still observed in the presence of CHX, indicating that this recovery
of TrxR activity did not depend on protein synthesis. To conﬁrm
the efﬁcacy of CHX, we veriﬁed its effect on acrolein-mediated
induction of heme oxygenase 1 (HO-1), which showed that CHX
completely prevented acrolein-induced upregulation of HO-1
(Fig. 2B). Total levels of TrxR were relatively unaltered under the
same conditions (Fig. 2B). Thus, these ﬁndings indicate that inacti-
vation and recovery of TrxR activity are not related to changes in
overall TrxR1 protein levels, but are likely related to reversible
post-translational modiﬁcation of TrxR by e.g. alkylation.
3.2. Acrolein induces transient carbonylation of cellular proteins and
TrxR1, independent of proteasomal activity
Following up on our previous ﬁndings indicating that acrolein-
induced inactivation of TrxR is related to alkylation at its seleno-
cysteine residue [7], we explored whether such alkylation may
be reversible over time. Using biotin hydrazide tagging to detect
protein–acrolein Michael adducts, we detected rapid increases in
acrolein-adducted proteins that disappeared with an approximate
half-life of 4 h, consistent with earlier ﬁndings [7,31]. Importantly,Fig. 2. Recovery of TrxR activity does not require protein synthesis. HBE1 cells were
pretreated with CHX followed by a 30 min 30 lM acrolein treatment with or
without an 8 h recovery period. (A) TrxR activity was measured by insulin assay at
indicated time-points, and expressed as mean ± S.E.M. (n = 4). ⁄⁄P < 0.01. Signiﬁ-
cance was designated after analysis by one-way ANOVA. (B) Western blot analysis
of HO-1, TrxR1 protein, and b-actin at indicated time points. Representative blots of
2 independent experiments are shown.
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with the observed kinetics of regeneration of TrxR activity, which
also occurred with a half-time of 4 h. We rationalized that the
gradual disappearance of carbonylated proteins may be due to pro-
teasomal degradation of alkylated (and thus damaged) proteins or
to metabolism of protein-bound carbonyls by e.g. aldehyde
dehydrogenases, so that they were no longer be detectable using
hydrazide labeling. To address the importance of proteasomal deg-
radation, experiments were performed in the presence of the 26S
proteasome inhibitor MG132, which showed that the disappear-
ance of hydrazide-detectable protein carbonyl adducts was not af-
fected (Fig. 3). Similary, acrolein-induced carbonylation of TrxR1
itself, previously demonstrated to result in its inactivation [7],
was signiﬁcantly decreased at 4 h after acrolein exposure, both in
the absence or presence of MG132 (Fig. 3). These ﬁndings indicate
that the reversal of TrxR activity after acrolein exposure is
associated with a loss of protein–acrolein adducts within TrxR,
independent of protein turnover and potentially by reversal of
acrolein-mediated alkylation of TrxR.
3.3. Reversal of TrxR activity and protein carbonylation depend on the
presence of GSH and Trx1
Based on the observed rapid recovery of cellular GSH levels
prior to restoration of TrxR activity (Fig. 1), we considered that
GSH may be involved in the regeneration of TrxR activity. To test
this, HBE1 cells were treated with the GSH synthesis inhibitor
BSO, immediately following a 30-min acrolein treatment, to mon-
itor its impact of GSH regeneration on recovery of TrxR activity
over time. As expected, BSO treatment completely prevented the
rapid repletion of GSH after acrolein treatment (Fig. 4A), although
it did not signiﬁcantly increase cytotoxicity (not shown). Moreover,Fig. 3. Disappearance of protein–acrolein adducts is not mediated by the 26S
proteasome. HBE1 cells were pretreated with MG132, followed by 30 min incuba-
tion with 30 lM acrolein with or without a 4 h recovery period. Carbonylated
proteins representing acrolein Michael adducts were analyzed by biotin hydrazide
labeling, and biotin labeling of cellular proteins was detected by streptavidin
blotting (top panel). Neutravidin-puriﬁed biotin hydrazide labeled proteins were
analyzed by Western blot using a-TrxR1 (middle panel) in comparison with similar
TrxR1 analysis in whole cell lysates (bottom panel). Blots are representative of 2
independent experiments.BSO treatment was also found to signiﬁcantly attenuate the grad-
ual recovery of TrxR activity over 8 h (Fig. 4B), suggesting that this
recovery may be related to GSH-dependent reversal of protein
alkylation. To test this, we evaluated hydrazide-detectable pro-
tein–acrolein adducts in whole cell lysates after acrolein treat-
ment, which indicated that BSO treatment slightly attenuated the
disappearance of protein carbonyl adducts in general, especially
at 2 h (Fig. 4C), suggesting a possible role for GSH in reversal of
protein carbonylation by acrolein. To more speciﬁcally evaluate
carbonylation of TrxR1 or other known target proteins for acrolein,
biotin hydrazide-labeled proteins were avidin-puriﬁed and ana-
lyzed by Western blotting for speciﬁc target proteins. Results in
Fig. 4D and E indicate that BSO treatment signiﬁcantly delays loss
of carbonylated TrxR1 over time, and also appears to impair loss of
carbonylated forms of Trx1 and JNK, two other target proteins for
acrolein [26,31], suggesting a role of GSH-dependent mechanisms
in reversal of alkylation of these proteins.
Our recent studies indicated that acrolein exposure induces
alkylation of Trx1, which critically depended on the presence of
TrxR1 [26]. One potential explanation for this ﬁnding is that alkyl-
ation of Trx1 occurs by a trans-alkylation mechanism after initial
alkylation of TrxR1. Consistent with this suggestion is our observa-
tion of sustained and even increasing carbonylation of Trx1 over 2–
8 h while carbonylation of TrxR1 decreases, particularly in the
presence of BSO (Fig. 4E). Consequently, Trx1 (as the substrate
for TrxR1) may contribute to regenerating TrxR activity after inac-
tivation by acrolein or other electrophiles. To assess the contribu-
tion of Trx1 to regeneration of TrxR activity, Trx1 expression was
silenced using siRNA prior to acrolein treatment. As shown in
Fig. 5A, Trx1 siRNA did not signiﬁcantly affect initial inactivation
of TrxR by acrolein, but markedly prevented its recovery over a
subsequent 8 h period. Notably, Trx1 siRNA pretreatment slightly
enhanced the cytotoxic effects of acrolein (from 15.3 ± 3.2% in
NT-siRNA transfected cells to 33.0 ± 6.1% in Trx1-siRNA transfected
cells), although this cannot fully explain the complete lack of TrxR
recovery in the absence of Trx1. Correspondingly, the reversal of
TrxR1 alkylation, as assessed by biotin hydrazide labeling, was also
attenuated after Trx1 siRNA knockdown (Fig. 5B).4. Discussion
Acrolein is a reactive electrophile, and an important environ-
mental pollutant of considerable health concern [1,36], and is be-
lieved to contribute to the adverse health effects of tobacco
smoking [7,26,31]. However, acrolein is also formed endogenously
by various deﬁned oxidative processes, and may therefore share
features of other biological electrophiles, such as cyclopentenone
prostaglandins [37], nitrated fatty acids [38], or nitrated nucleo-
tides [39], that have been considered to act as intracellular mes-
sengers with deﬁned speciﬁc cellular functions. Since each of
these electrophiles largely act by covalent Michael addition, pri-
marily to susceptible cysteine residues, such electrophile signaling
represents another component of thiol-dependent redox signaling,
similar to e.g. S-nitrosylation or S-glutathionylation [40,41]. How-
ever, in contrast to these oxidative mechanisms of thiol-based re-
dox signaling, S-alkylation by e.g. a,b-unsaturated aldehydes is
typically considered irreversible, although chemical studies indi-
cate that they can reversed in the presence of excess thiols. It is,
therefore, plausible that endogenous thiol-based mechanisms exist
to reverse S-alkylation in biological systems in vivo, which would
further support its importance as a biologically important signaling
mechanism. Indeed, our present ﬁndings strongly suggest that
acrolein-dependent covalent protein modiﬁcations are biologically
reversible by endogenous reducing mechanisms involving GSH
and/or Trx1, and that such reversal mechanisms help restore
Fig. 4. Recovery of TrxR activity and reversal of protein carbonylation depends on GSH status. HBE1 cells were treated with 30 lM acrolein for 15 min, and subsequently
incubated for up to 8 h in the absence or presence of 100 lM BSO. At indicated time points, cell lysates were evaluated for GSH by HPLC (A) or for TrxR activity using the
insulin assay (B). Results are expressed as mean ± S.E.M., n = 4. ⁄P < 0.05. Signiﬁcance was designated after analysis by multiple t-tests. Carbonylated proteins were analyzed
by biotin hydrazide labeling and streptavidin blot (C) or neutravidin puriﬁed for analysis by Western blotting using antibodies against Trx1, JNK, or TrxR1 (D). Comparative
Western blot analysis of Trx1, JNK, or TrxR1 was performed on whole cell lysates. Relative band densities of biotinylated TrxR1, Trx1, and JNK were normalized to overall
protein levels and expressed relative to levels observed after 30 min (0.5 hrs) acrolein treatment (E). Mean ± S.E.M from 4 replicates from 2 separate experiments are shown.
⁄P < 0.05.
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feasible that other key target proteins for acrolein or other electro-
philes may be restored by similar reducing mechanisms. Although
the present studies were performed with a single cell line, our pre-
vious studies similarly indicate reversible protein alkylation in
other cell types [31], and suggest that these reversal mechanisms
may be universal.
It should be noted that the use of biotin hydrazide labeling to
detect acrolein-dependent protein Michael adducts has theinherent limitation that it also detects other protein carbonyls that
are formed more indirectly by e.g. acrolein-mediated oxidative
events. Moreover, disappearance of protein carbonyl moieties over
time does not necessarily indicate reversal of Michael adducts, but
most likely also represents additional reactions of protein-bound
carbonyls (e.g. through Schiff bases [12]) or metabolism of pro-
tein-bound carbonyls by e.g. aldehyde dehydrogenases. However,
we previously established that acrolein-induced loss of TrxR activ-
ity is directly related to Michael addition to its selenocysteine
Fig. 5. Role of Trx1 in reversal of TrxR1 alkylation and recovery of activity. HBE1 cells were pretreated with Trx1-targeted siRNA and exposure to 30 lM acrolein for 30 min,
followed by 8 h recovery. (A) Analysis of TrxR activity at indicated time points in NT-siRNA or Trx1 siRNA-transfected cells. Data represent mean ± S.E.M. (n = 3). ⁄P < 0.05.
Signiﬁcance was designated after analysis by two-way ANOVA. (B) Puriﬁed biotin hydrazide-derivatized proteins were analyzed by Western blot for TrxR1. Total TrxR1 and
Trx1 were also analyzed in corresponding whole cell lysates. Representative blots from duplicate experiments are shown.
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kinetically with disappearance of biotin hydrazide-detectable pro-
tein carbonyls within the TrxR1, and is not associated with signif-
icant changes in overall TrxR1 protein levels under the same
conditions, strongly suggests that such restoration of TrxR is med-
iated by reversal of acrolein adduction to its selenocysteine resi-
due. Our ﬁnding that such reversal depends of the presence of
Trx1, a speciﬁc substrate for TrxR1, further supports this notion.
Our results indicate the involvement of both GSH and Trx1 in
promoting the regeneration of TrxR activity after its inactivation
by acrolein. Based on previous ﬁndings that indicate a role for
GST in catalyzing retro Michael addition by various electrophiles
[21–23], we propose that GSH-dependent restoration of TrxR1
activity, or of other proteins such as Trx1 or JNK (Fig. 4), may sim-
ilarly depend on GST activity. Restoration of TrxR alkylation and
activity was also found to critically depend on Trx1, which may
be uniquely involved in initial regeneration of TrxR1 by a trans-
alkylation mechanism. Such a mechanism would be consistent
with our recent ﬁnding that detection of acrolein-adducted Trx1
in acrolein-exposed HBE1 cells was strongly dependent on the
presence of TrxR1 [26], which could suggest that alkylation of
Trx1 may have largely occurred indirectly after initial alkylation
of the more reactive selenocysteine within TrxR1. In turn, reversal
of alkylated Trx1 by GSH-dependent mechanisms may contribute
to full recovery of TrxR. Future studies using puriﬁed or recombi-
nant enzymes in cell-free systems would be required to more
deﬁnitively conﬁrm the concept of transalkylation in regulation
of TrxR.
In summary, our present ﬁndings strongly imply that covalent
alkylation of protein thiols by biological electrophiles such as acro-
lein can be reversed by endogenous GSH- and Trx-dependentmech-anisms. These ﬁndings indicate that, rather than representing
irreversible protein damage, protein alkylation by acrolein and
other electrophiles may be an important reversible event in adap-
tive responses to electrophilic stress or function as electrophile-spe-
ciﬁc signalingmechanism analoguous to e.g. protein S-nitrosylation
or S-glutathionylation. A more complete understanding of such
reversal mechanisms would not only offer better insight into the
biological functions of electrophiles but may also contribute to im-
proved strategies tomanage chronic pulmonary diseases associated
with environmental acrolein exposure or cigarette smoking.References
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